The US is about to get a healthy dose of British tech as Medopad announces its expansion into the heart of the country‘s complex healthcare system.
The healthtech company has announced it will be taking up a new office in the heart of New York City at Johnson & Johnson’s (J&J’s) new JLABS office. As part of the launch, Medopad will hire top healthtech talent before the end of the year.
New York City is an established nucleus for the life sciences industry, home to the largest concentration of academic institutions in the world, making it an ideal launchpad into the US.
Furthermore, New York boasts the largest workforce in bioscience across the country working at more than 120 companies.
“We are thrilled to open a base in the USA as part of Johnson & Johnson’s incubator platform JLABS,” said Medopad CEO Dan Vahdat.
“This is a fantastic opportunity for Medopad as our values and vision are aligned with J&J’s leadership to help create a world where people can live longer. We value this partnership are looking forward to moving into our new office.
“We have been working in partnership with US pharmaceuticals, healthcare providers and academic institutions such as Johns Hopkins where Medopad is used to connect clinicians to patients remotely and collect real world evidence.
“We look forward to strengthening these bonds and driving more innovative change for better health outcomes for people. The remote patient monitoring market is more than eight times bigger in the US versus the UK.”
The JLABS model is specifically designed to help life science entrepreneurs gain access to the equipment, mentors, resources and experiences they need to bring their companies forward.
Earlier this year, Medopad joined ‘Plug and Play’ a global innovation platform in California. Headquartered in Silicon Valley, their programme is centred on business development.
Through this Medopad will be able to secure pilots, POCs, and investments from Plug and Play’s extensive network of 220 corporate partners.
“The healthcare industry is highly regulated and deeply complex, change is slower than is needed,” said Vahdat.
“Our disruptive healthcare patient monitoring solution will help bring great ideas from bench to bedside.”
Medopad has seen 400 per cent growth in the value of signed projects year-on-year since 2015 including The Royal Free, Guys, St Thomas’s, GSK, Johnson & Johnson and Boston Scientific.
In the last 12 months it has been awarded Champion of the European Accenture HealthTech Innovation Challenge, as well as ‘Best Healthcare Technology of the Year’ at the National Technology Awards.
KPMG also named Medopad a ‘US$1bn healthtech company in the making’.